Edition:
United States

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

81.44USD
16 Feb 2018
Change (% chg)

$-1.11 (-1.34%)
Prev Close
$82.55
Open
$81.94
Day's High
$84.03
Day's Low
$81.23
Volume
76,248
Avg. Vol
168,200
52-wk High
$92.00
52-wk Low
$32.98

Latest Key Developments (Source: Significant Developments)

Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share
Tuesday, 12 Dec 2017 10:49pm EST 

Dec 12 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.70 MILLION COMMON SHARES PRICED AT $81.00PER SHARE.  Full Article

Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
Monday, 11 Dec 2017 04:01pm EST 

Dec 11 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK.BLUEPRINT MEDICINES CORP SAYS IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $275.0 MILLION IN SHARES OF ITS COMMON STOCK.BLUEPRINT MEDICINES-EXPECTS TO USE PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR AVAPRITINIB IN GASTROINTESTINAL STROMAL TUMORS,SYSTEMIC MASTOCYTOSIS.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-554 IN HEPATOCELLULAR CARCINOMA.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-667 IN RET-DRIVEN CANCERS.  Full Article

Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285
Friday, 10 Nov 2017 09:05am EST 

Nov 10 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes.Blueprint Medicines Corp - ‍new cohort in second-line gist added to ongoing phase 1 trial​.Blueprint Medicines Corp - ‍global, randomized phase 3 trial in third-line gist on track to initiate in first half 2018​.  Full Article

Blueprint Medicines Q3 loss per share $0.96
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports third quarter 2017 financial results.Q3 loss per share $0.96.Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​.Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​.  Full Article

Blueprint Medicines Q2 loss per share $0.86
Wednesday, 2 Aug 2017 07:00am EDT 

Aug 2 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports second quarter 2017 financial results.Q2 loss per share $0.86.Q2 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S.  Full Article

Blueprint Medicines to evaluate advance disease discovery program opportunities
Thursday, 27 Jul 2017 06:35am EDT 

July 27 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion.Says received written notice from Alexion of its decision to discontinue collaboration.Says believe existing cash, cash equivalents, excluding some items, to be sufficient to fund expenditure requirements into 2H 2019.  Full Article

Blueprint Medicines announces new phase 1 clinical data for Blu-285
Monday, 5 Jun 2017 08:00am EDT 

June 5 (Reuters) - Blueprint Medicines Corp ::Blueprint medicines announces new phase 1 clinical data for Blu-285 in advanced gastrointestinal stromal tumors and plans to pursue expedited development in patients with a pdgfrα d842v mutation.‍Blu-285 was well tolerated, and most adverse events reported by investigators were grade 1 or 2.​.FDA granted breakthrough therapy designation to Blu-285 for treatment of patients with unresectable or metastatic pdgfrα d842v-driven gist​.‍Additional data from expansion portion of ongoing trial of Blu-285 may be sufficient to support nda for treatment of patients with pdgfrα d842v-driven gist.‍company also plans to initiate a global, pivotal phase 3 clinical trial of Blu-285 in first half of 2018​.  Full Article

Blueprint Medicines Q1 loss per share $0.84
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Blueprint Medicines Corp ::Blueprint Medicines reports first quarter 2017 financial results.Q1 loss per share $0.84.Q1 earnings per share view $-0.76 -- Thomson Reuters I/B/E/S.Blueprint Medicines - as of march 31, 2017, cash, cash equivalents and investments were $236.3 million, as compared to $268.2 million as of december 31, 2016..  Full Article

Blueprint Medicines announces pricing of public offering of shares of common stock
Wednesday, 29 Mar 2017 06:55pm EDT 

Blueprint Medicines Corp : Blueprint Medicines announces pricing of public offering of shares of common stock .Blueprint Medicines - Announced pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $40.00 per share.  Full Article

Blueprint Medicines announces public offering of shares of common stock
Wednesday, 29 Mar 2017 07:30am EDT 

Blueprint Medicines Corp : Blueprint Medicines announces proposed public offering of shares of common stock . Blueprint Medicines Corp - commenced an underwritten public offering of $150 million in shares of its common stock .Blueprint Medicines-expects to use proceeds to fund clinical trials for blu-285 in gist and sm, fund clinical trials for blu-554 in HCC, among others.  Full Article